

## Original Article

# Beta-amyloid toxicity modifier genes and the risk of Alzheimer's disease

Samantha L Rosenthal<sup>1</sup>, Xingbin Wang<sup>1</sup>, F Yesim Demirci<sup>1</sup>, Michael M Barmada<sup>1</sup>, Mary Ganguli<sup>2,4,5</sup>, Oscar L Lopez<sup>3,4</sup>, M Ilyas Kamboh<sup>1,2,3,5</sup>

<sup>1</sup>Department of Human Genetics, University Pittsburgh, Pittsburgh, PA, USA; <sup>2</sup>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA; <sup>3</sup>Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA, USA; <sup>4</sup>Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA; <sup>5</sup>Department of Epidemiology, University of Pittsburgh, PA, USA.

Received July 31, 2012; accepted August 10, 2012; Epub August 13, 2012; published August 15, 2012

**Abstract:** Late-onset Alzheimer's disease (LOAD) is a complex and multifactorial disease. So far ten loci have been identified for LOAD, including *APOE*, *PICALM*, *CLU*, *BIN1*, *CD2AP*, *CR1*, *CD33*, *EPHA1*, *ABCA7*, and *MS4A4A/MS4A6E*, but they explain about 50% of the genetic risk and thus additional risk genes need to be identified. Amyloid beta (A $\beta$ ) plaques develop in the brains of LOAD patients and are considered to be a pathological hallmark of this disease. Recently 12 new A $\beta$  toxicity modifier genes (*ADSSL1*, *PICALM*, *SH3KBP1*, *XRN1*, *SNX8*, *PPP2R5C*, *FBXL2*, *MAP2K4*, *SYNJ1*, *RABGEF1*, *POMT2*, and *XPO1*) have been identified that potentially play a role in LOAD risk. In this study, we have examined the association of 222 SNPs in these 12 candidate genes with LOAD risk in 1291 LOAD cases and 958 cognitively normal controls. Single site and haplotype analyses were performed using PLINK. Following adjustment for *APOE* genotype, age, sex, and principal components, we found single nucleotide polymorphisms (SNPs) in *PPP2R5C*, *PICALM*, *SH3KBP1*, *XRN1*, and *SNX8* that showed significant association with risk of LOAD. The top SNP was located in intron 3 of *PPP2R5C* (P=0.009017), followed by an intron 19 SNP in *PICALM* (P=0.0102). Haplotype analysis revealed significant associations in *ADSSL1*, *PICALM*, *PPP2R5C*, *SNX8*, and *SH3KBP1* genes. Our data indicate that genetic variation in these new candidate genes affects the risk of LOAD. Further investigation of these genes, including additional replication in other case-control samples and functional studies to elucidate the pathways by which they affect A $\beta$ , are necessary to determine the degree of involvement these genes have for LOAD risk.

**Keywords:** Late-onset Alzheimer's disease (LOAD), risk genes, SNPs, *ADSSL1*, *PICALM*, *SH3KBP1*, *XRN1*, *SNX8*, *PPP2R5C*, *FBXL2*, *MAP2K4*, *SYNJ1*, *RABGEF1*, *POMT2*, *XPO1*,

## Introduction

Alzheimer's disease (AD) is a devastating neurodegenerative disease, affecting an estimated 5.3 million people aged 65 and older in the United States [1]. Characterized by a classic combination of both intracellular and extracellular pathologies, neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein within neurons and accumulation of  $\beta$ -amyloid (A $\beta$ ) senile plaques in the brain, AD results in progressive memory loss and cognitive impairment [2]. Although there is still debate whether A $\beta$  or NFTs are the cause or consequence of the disease, evidence suggest that A $\beta$  acts upstream of NFTs [3, 4] and thus is an important contributor to the initiation of AD. The role of A $\beta$  in the rare familial form of early onset AD (EOAD) is well

established where disease-associated mutations in three genes, amyloid precursor protein (*APP*), and *presenilin 1* and *2* (*PSEN1*, *PSEN2*), are associated with elevated levels of A $\beta$  42 or A $\beta$  42/40 [5]. However, the role of A $\beta$  in the common and multifactorial late onset form of AD (LOAD) is not well defined. Thus far genome-wide association studies (GWASs) have identified ten susceptibility loci for LOAD, including *APOE*, *CLU*, *CR1*, *PICALM*, *BIN1*, *CD2AP*, *CD33*, *EPHA1*, *ABCA7* and *MS4A4/MS4A6E* [6-10]. With the exception of *APOE* that affects A $\beta$  deposition and clearance in the brain [2], the role of other nine known loci in A $\beta$  metabolism is not clear.

Recently, Treusch *et al.* [11] modeled A $\beta$  toxicity in yeast and identified forty hits, twelve of which

were found to be human homologs, including eight A $\beta$  toxicity suppressor (*ADSSLI*, *PICALM*, *SH3KBP1*, *PPP2R5C*, *FBXL2*, *SYNJ1*, *RABGEF1*, and *XPO1*) and four A $\beta$  toxicity enhancer genes (*XRN1*, *SNX8*, *MAP2K4*, and *POMT2*) whose relationship to A $\beta$  was previously unknown. One of these human homologs is a recently identified gene for LOAD (*PICALM*), and two of them (*SH3KBP1* and *SYNJ1*) interact with two additional known genes for LOAD (*BIN1* and *CD2AP*, respectively). Recently, we have reported the association of *PICALM*, *BIN1* and *CD2AP* gene variation with LOAD risk [12]. In this study we have comprehensively examined the association of 222 single-nucleotide polymorphisms (SNPs) in the twelve A $\beta$  toxicity modifier genes with LOAD risk in a large case-control sample.

### Materials and Methods

#### Samples

A total of 2,440 Caucasian American subjects, including 1,440 LOAD cases (mean age-at-onset  $72.6 \pm 6.4$  years, 66% women, 24% autopsy-confirmed) and 1,000 controls (mean age  $74.07 \pm 6.20$  years, 60% women) were recruited with informed consent. LOAD cases were selected from University of Pittsburgh Alzheimer's Disease Research Center (ADRC), and controls, aged 60 and older, were cognitively normal individuals recruited from the same geographic region as the cases. All cases met the National Institute of Neurological and Communication Disorders and Stroke (NINCDS)/ Alzheimer's Disease and Related Disorders Association (ADDA) criteria for probable or definite AD, and were evaluated by the University of Pittsburgh ADRC's standard protocol, including medical history, general medical and neurological examination, psychiatric interview, neurophysiological testing and MRI scan. The study was approved by the University of Pittsburgh Internal Review Board.

#### Genotyping

The Illumina Omni1-Quad chip was used to genotype all samples. Following standard quality control and exclusion criteria, 2,249 subjects (1,291 LOAD cases and 958 controls) were included in the final analysis as described elsewhere [12]. There were a total of 222 SNPs present on the Illumina chip in the 12 candidate genes examined (*ADSSLI*, *PICALM*, *SH3KBP1*,

*XRN1*, *SNX8*, *PPP2R5C*, *FBXL2*, *MAP2K4*, *SYNJ1*, *RABGEF1*, *POMT2* and *XPO1*).

#### Single locus analysis

Association of 222 SNPs located in 12 new A $\beta$  toxicity modifier genes was tested using logistic regression under an additive model adjusting for age, sex, and the first four principal components as covariates using PLINK [13]. Further adjustment was made for *APOE* genotype following initial association test.

#### Haplotype Analysis

Haplotype analysis within each gene was performed using a sliding-windows approach with *haplo.glm* function in the Haplo.Stats R package (version 1.5.5). The global p-value measures significance of the entire set of haplotypes for the locus subset. In the analysis, we included 4 SNPs per window. Only SNPs with allele frequencies of 0.01 and higher in the pooled case-control sample were included in the analysis. Since the *SH3KBP1* gene is located on the X chromosome, we performed haplotype analysis separately in males and females.

### Results

#### Single locus analysis

Of the 222 SNPs tested, 21 SNPs in 5 genes showed nominal significant associations with AD risk ( $P < 0.05$ ). Following *APOE* adjustment, 14 SNPs in 5 genes—*PPP2R5C*, *PICALM*, *SH3KBP1*, *XRN1*, and *SNX8* remained significant at  $\alpha = 0.05$ . The most significant SNP, rs1746595 ( $P = 9.01E-03$ ), was located in intron 3 of *PPP2R5C*, followed by rs10501602 ( $P = 1.04E-02$ ) in intron 19 of *PICALM*. Interestingly, a SNP located in *PICALM* (rs10792820) become more significant following *APOE* adjustment. Despite these findings, none of these SNPs remained significant after correcting for gene-based multiple comparisons. The strongest associations for each gene pre- and post-*APOE* adjustment are displayed in **Table 1**. Results for all loci tested can be found in [Supplementary Table 1](#).

#### Haplotype analysis

Five of the 12 genes examined (*ADSSLI*, *PICALM*, *PPP2R5C*, *SNX8*, and *SH3KBP1*) showed

## Aβ toxicity modifier genes and the risk of AD

**Table 1.** Most significant SNP for each gene tested in single site analysis

Gene	Chr <sup>1</sup>	SNP	A1 <sup>2</sup>	OR <sup>3</sup>	P-unadjusted <sup>4</sup>	APOE adj.-P <sup>5</sup>
<i>XPO1</i>	2	rs10186325	C	1.088	0.1896	0.132
<i>XRN1</i>	3	rs1351965	A	1.186	0.01117	0.01861
<i>FBXL2</i>	3	rs6777187	A	1.076	0.2848	0.7143
<i>FBXL2</i>	3	rs13087731	G	0.9511	0.4493	0.308
<i>SNX8</i>	7	rs2286206	A	1.554	0.01335	0.09287
<i>SNX8</i>	7	rs10249052	A	1.167	0.02036	0.04795
<i>RABGEF1</i>	7	rs4717322	A	1.151	0.1076	0.2701
<i>RABGEF1</i>	7	GA006396	G	0.8145	0.2057	0.1767
<i>PICALM</i>	11	rs10501602	G	0.7217	0.0006709	0.01037
<i>PPP2R5C</i>	14	rs1746595	G	1.235	0.004142	0.009017
<i>POMT2</i>	14	rs2363640	A	0.8732	0.07975	0.08041
<i>ADSSL1</i>	14	rs4983382	G	0.9188	0.2467	0.222
<i>MAP2K4</i>	17	rs28921114	I	1.498	0.1387	0.1342
<i>SYNJ1</i>	21	rs2833930	A	0.9047	0.1407	0.05831
<i>SH3KBP1</i>	X	rs12013533	G	0.7977	0.006109	0.01496

<sup>1</sup>Chromosome location; <sup>2</sup>Effect allele; <sup>3</sup>Odds ratio; <sup>4</sup>Unadjusted P-value; <sup>5</sup>P value adjusted for APOE genotype

significant haplotype window associations with LOAD (**Figure 1**; [Supplementary Table 2](#)). The most significant association in this sample was for *ADSSL1*/SNPs rs11160818 - rs4983382-rs35590716 - rs34672588 ( $P=3.72E-03$ ). The next significant association was observed with *PPP2R5C*/SNPs rs1677999 - rs1741140 - rs2749907 - rs16779919 ( $P=5.10E-03$ ). *PICALM* and *SNX8* yielded significant effects as well, each containing three significant associations. For *SH3KBP1*, we observed six significant associations in males only, with the most significant association being in a window containing SNPs: rs16981251- rs4630061- rs11795873-rs11094775 ( $P=7.82E-03$ ). The 7 genes showing no significant windows in the haplotype analysis are illustrated in The 7 genes showing no significant windows in the haplotype analysis are illustrated in The 7 genes showing no significant windows in the haplotype analysis are illustrated in **Figure 2**.


### Discussion

Our data indicate that genetic variation in 6 of the 12 recently described Aβ toxicity modifier genes affects the risk of LOAD at a nominal  $P<0.05$ . Since these are biological candidate genes for LOAD, we consider  $P<0.05$  to be an indication of potential real association that should be followed by comprehensive resequencing of these genes to find functional variants. One of these Aβ toxicity modifier genes,

*PICALM*, has been repeatedly implicated as a risk locus for LOAD in other studies [7, 9, 10, 12, 14, 15], and we have replicated similar findings. In our sample, *PICALM* contained four SNPs (rs10501602, rs694011, rs609903, rs10792820) with a significant association following APOE adjustment, as well as three adjacent windows with significant haplotypes. While its exact function in AD pathogenesis is unclear, it has been suggested that *PICALM* plays a role in the processing of amyloid precursor protein (APP), the precursor to both amyloidogenic oligomers and non-pathogenic peptides [16]. More recent work has suggested a more specific role as a suppressor of Aβ toxicity rather than a mediator of Aβ production [11]. Our identification of *PICALM*'s association with LOAD risk in both single and multi-site analysis complements the many other findings regarding its role in AD.


*PPP2R5C* (*B56γ-PP2A*) also showed significant association in both single locus and haplotype analyses. The only SNP (rs1746595) in this gene that showed significant association was also the most significant SNP in our sample ( $P=9.017E-03$ ). Interestingly, neither of the significant windows from haplotype analysis for this gene contained this putative SNP. A member of a group of phosphoprotein phosphatase genes, *PPP2R5C* is largely recognized as a tumor suppressor gene [17, 18]. Investigation of its role in LOAD has been minimal despite its

## Aβ toxicity modifier genes and the risk of AD



**Figure 1.** Haplotype windows for genes containing significant windows. Lines represent the window tested, with the corresponding SNP rs numbers along the horizontal axis and global p-value on the vertical axis. Significant associations fall above the reference line (dotted) at  $-\log_{10}(0.05) = 1.3$ .

## Aβ toxicity modifier genes and the risk of AD



**Figure 2.** Haplotype windows for genes containing no significant windows. Lines represent the window tested, with the corresponding SNP rs numbers along the horizontal axis and global p-value on the vertical axis.

detection as a possible risk locus in a few previous studies [4], specifically with regard to abnormal Tau protein [19]. Combined with our findings and those of Treusch, more work concerning the role of *PPP2R5C* and its fellow phosphoprotein phosphatases in AD should be undertaken.

*SNX8* and *XRN1* have been identified as A $\beta$  toxicity enhancers [11]. *XRN1* contained four APOE-adjusted significant SNPs (rs1351965, rs13061823, rs6440082, rs3816805), however, we did not identify any significant windows for haplotype analysis. *SNX8* showed significant associations for both analyses, with a single significant SNP (rs10249052) and three significant windows, two of which contained the suggestive SNP from single locus analysis. Though no mechanism has been proposed to explain how these genes elevate the toxicity of A $\beta$ , the role of *SNX8* in endosomal content sorting [20] fits well with the implication of clathrin-mediated endocytosis (CME) in LOAD risk [11, 21].

*ADSSL1* is an intracellular protein responsible for catalyzing the first step of *de novo* biosynthesis of AMP [22, 23] and its genetic variation has been shown to affect AD neuropathology and episodic memory [11]. While this gene lacked significance in our single locus analysis, it possessed the most significant window in haplotype analysis ( $P=3.724E-03$ ), suggesting that it may be relevant to LOAD risk. *SH3KBP1* (*CIN85*) has been implicated in clathrin-mediated endocytosis (CME) of epidermal growth factor receptor (EGFR) [24] and is a member of Src family kinases that can phosphorylate Tau to produce the second pathological hallmark of LOAD, NFTs [19]. In this study we found both single and multi-locus associations in this gene, further confirming its possible role in LOAD.

Previously, genetic variation in *XPO1* has been reported to be associated with AD in a family-based sample [11]. However, we did not find significant associations in *XPO1* in our case-control sample. Likewise, we did not find associations in 5 additional genes (*FBXL2*, *RABGEF1*, *MAP2K4*, *POMT2*, and *SYNJ1*). The lack of association with these 6 genes does not mean they are not relevant to LOAD risk. LOAD is a multifactorial disease with a number of genes that potentially affect its development and severity. Given this complexity, it is quite

plausible that our sample did not contain enough individuals who possessed the causative alleles in these genes. Additionally, our study used only genotyped SNPs in our data set. It is possible that the functional variants affecting A $\beta$  toxicity in these genes were not genotyped in our samples or were not in linkage disequilibrium with the genotyped variants.

Further investigation of these genes, including additional replication in other case-control samples, resequencing, and functional studies to elucidate the pathways by which they affect A $\beta$  toxicity, are necessary to determine the degree of involvement these genes have for LOAD risk. Similar findings would suggest potential therapies that seek to increase expression of genes identified as suppressors of A $\beta$  toxicity or to downregulate production of proteins that enhance A $\beta$  toxicity. However, targeted therapies such as these cannot begin development until the mechanisms of AD are better understood.

### Acknowledgements

This study was supported by the National Institute on Aging Grants AG030653, AG005133, AG07562 and AG023651.

**Please address correspondence to:** M. Ilyas Kamboh, PhD, Department of Human Genetics, Graduate School of Public Health University of Pittsburgh, Pittsburgh, PA 15161, USA. Telephone: 412-624-3066; Fax: 412-624-3020; E-mail: kamboh@pitt.edu

### References

- [1] Barnes DE and Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol* 2011; 10:819-828.
- [2] Holtzman DM, Morris JC, and Goate AM. Alzheimer's disease: the challenge of the second century. *Sci Transl Med* 2011; 3: 77sr1.
- [3] Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer's disease. *Arch Neurol* 2011; 68(8): 1062-1064.
- [4] Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, Casseli RJ, Kukull WA, McKeel D, Morris JC, Hulette CM, Schmechel D, Reiman EM, Rogers J, and Stephan DA. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: A reference data set. *Physiol Genomics* 2008; 33: 240-256
- [5] Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, and Younkin S.

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's Disease. *Nat Med* 1996; 2:864-870.

- [6] Lambert, JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O; European Alzheimer's Disease Initiative Investigators, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanché H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, and Amouyel P. Genome-wide association study identifies variants at *CLU* and *CR1* associated with Alzheimer's disease. *Nat Genet* 2009; 41: 1094-1099.
- [7] Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at *CLU* and *PICALM* associated with Alzheimer's disease. *Nat Genet* 2009; 41: 1088-1093.
- [8] Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Vardarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, Breteler MM; CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer's disease. *JAMA* 2010; 303: 1832-1840.
- [9] Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Rutherford E, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Gallacher J, Hüll M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcicowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC; Alzheimer's Disease Neuroimaging Initiative, van Duijn CM, Breteler MM, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S; CHARGE consortium, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M; EADI1 consortium, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Björnsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossù P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J. Common variants at *ABCA7*, *MS4A6A/MS4A4E*, *EPHA1*, *CD22*, and *CD2AP* are associated with Alzheimer's disease. *Nat Genet* 2011; 43: 429-435.
- [10] Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buross J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D,

- Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, and Schellenberg GD. Common variants at MS4A4/MS4A6E, CD2AP, CD33, and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet* 2011; 43: 436-441.
- [11] Treusch S, Hamamichi S, Goodman JL, Matlack KES, Chung CY, Baru V, Shulman JM, Parrado A, Bevis BJ, Valastyan JS, Han H, Lindhagen-Persson M, Reiman EM, Evans DA, Bennett DA, Olofsson A, DeJager PL, Tanzi RE, Caldwell KA, Caldwell GA, and Lindquist S. Functional links between A $\beta$  toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. *Science* 2011; 334: 1241-1245.
- [12] Kamboh MI, Demirci FY, Wang X, Minster RL, Carrasquillo MM, Pankratz VS, Younkin SG, Saykin AJ; The Alzheimer's Disease Neuroimaging Initiative, Sweet RA, Feingold E, DeKosky ST, Lopez OL. Genome-wide association study of Alzheimer's disease. *Transl Psychiatry* 2012; 2: e117, doi:10.1038/tp.2012.45.
- [13] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ & Sham PC (2007) PLINK: a toolset for whole-genome association and population-based linkage analysis. *Am J Hum Genet* 2007; 81:559-575.
- [14] Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, Nalls MA, Chen K, Lee W, Cheung K, Villa SE, Meechoovet HB, Gerber JD, Frost D, Benson HL, O'Reilly S, Chibnik LB, Shulman JM, Singleton AB, Craig DW, Van Keuren-Jensen KR, Dunckley T, Bennett DA, De Jager PL, Heward C, Hardy J, Reiman EM, and Huentelman MJ. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. *Hum Mol Genet* 2010; 19: 3295-3301.
- [15] Kok EH, Luoto T, Haikonen S, Goebeler S, Haapasalo H, and Karhunen PJ. CLU, CR1, and PICALM genes associated with Alzheimer's-related senile plaques. *Alzheimers Res Ther.* 2011; 3:12.
- [16] Xiao Q, Gil SC, Yan P, Wang Y, Han S, Gonzales E, Perez R, Cirrito JR, and Lee JM. Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. *J Biol Chem.* 2012; 287:21279-89.
- [17] Shouse GP, Nobumori Y, Panowicz MJ, and Liu X. ATM-mediated phosphorylation activates the tumor-suppressive function of B56 $\gamma$ -PP2A. *Oncogene* 2011; 30: 3755-3765.
- [18] Lee T-Y, Lai T-Y, Lin S-C, Wu C-W, Ni I-F, Yang Y-S, Hung L-Y, Law BK, and Chiang C-W. The B56 $\gamma$ 3 regulatory subunit of protein phosphatase 2A (PP2A) regulates S phase-specific nuclear accumulation of PP2A and the G<sub>1</sub> to S transition. *J Biol Chem* 2010; 285: 21567-21580.
- [19] Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin M-L, and Terro F. Tau protein phosphatases in Alzheimer's disease: The leading role of PP2A. *Ageing Res Rev* 2012; <http://dx.doi.org/10.1016/j.arr.2012.06.008> [Epub ahead of print].
- [20] Dyve AB, Bergan J, Utskarpen A, and Sandvig K. Sorting nexin 8 regulates endosome-to-Golgi transport. *Biochem Biophys Res Commun* 2009; 390: 109-114.
- [21] Wu F and Yao PJ. Clathrin-mediated endocytosis and Alzheimer's disease: an update. *Ageing Res Rev* 2009; 8:147-149.
- [22] Sun H, Li N, Wang X, Chen T, Shi L, Zhang L, Wang J, Wan T, and Cao X. Molecular cloning and characterization of a novel muscle adenylosuccinate synthetase AdSSL1, from human bone marrow stromal cells. *Mol Cell Biochem* 2005; 269: 85-94.
- [23] Lowenstein JM. Ammonia production in muscle and other tissues: The purine nucleotide cycle. *Physiol Rev* 1972; 52: 382-414.
- [24] Ronning SB, Pedersen NM, Madshus IH, and Stang E. CIN85 regulates ubiquitination and degradative endosomal sorting of the EGF receptor. *Exp Cell Res* 2011; 317: 1804-1816.



## A $\beta$ toxicity modifier genes and the risk of AD

**Supplementary Table 1.** Single locus analysis results for all 222 SNPs tested

Gene	Chr <sup>1</sup>	SNP	A1 <sup>2</sup>	OR <sup>3</sup>	P-unadjusted <sup>4</sup>	APOE adj.-P <sup>5</sup>
<i>XPO1</i>	2	rs10186325	C	1.088	0.1896	0.132
<i>XPO1</i>	2	rs6735330	A	0.8912	0.1901	0.2817
<i>XPO1</i>	2	rs3732171	G	1.083	0.2139	0.146
<i>XPO1</i>	2	rs4430924	A	1.057	0.3888	0.2238
<i>XPO1</i>	2	rs1050567	A	1.081	0.4273	0.5072
<i>XPO1</i>	2	rs11125886	G	0.8806	0.4482	0.664
<i>XPO1</i>	2	GA020328	A	0.9605	0.5278	0.4122
<i>XPO1</i>	2	rs11125883	C	0.9801	0.7569	0.4837
<i>FBXL2</i>	3	rs6777187	A	1.076	0.2848	0.7143
<i>FBXL2</i>	3	rs12486192	A	1.075	0.3011	0.7498
<i>FBXL2</i>	3	rs13078580	G	0.9178	0.3772	0.8279
<i>FBXL2</i>	3	rs17029976	A	1.076	0.4181	0.6195
<i>FBXL2</i>	3	rs13087731	G	0.9511	0.4493	0.308
<i>FBXL2</i>	3	rs17192791	A	1.185	0.4796	0.8741
<i>FBXL2</i>	3	rs2291897	A	1.055	0.5215	0.9214
<i>FBXL2</i>	3	rs7626634	G	1.045	0.6331	0.8882
<i>FBXL2</i>	3	rs4678929	C	1.041	0.6364	0.9386
<i>FBXL2</i>	3	rs4045539	C	1.039	0.6434	0.9521
<i>FBXL2</i>	3	rs10428231	G	1.046	0.666	0.7717
<i>FBXL2</i>	3	rs17805850	A	1.046	0.6665	0.7774
<i>FBXL2</i>	3	rs12486515	A	1.035	0.7429	0.8865
<i>FBXL2</i>	3	rs4678848	G	1.033	0.7603	0.9422
<i>FBXL2</i>	3	rs11260	A	1.072	0.7956	0.747
<i>FBXL2</i>	3	rs7640029	A	1.016	0.8131	0.8039
<i>XRN1</i>	3	rs1351965	A	1.186	0.01117	0.01861
<i>XRN1</i>	3	rs13061823	G	1.149	0.0271	0.03655
<i>XRN1</i>	3	rs6440082	G	1.148	0.02747	0.03821
<i>XRN1</i>	3	rs3816805	A	1.146	0.03006	0.04431
<i>XRN1</i>	3	rs9826786	A	1.126	0.0624	0.09096
<i>XRN1</i>	3	rs3762799	G	0.898	0.08623	0.05194
<i>XRN1</i>	3	rs1802904	G	0.8939	0.2035	0.3483
<i>XRN1</i>	3	rs10935463	G	0.9384	0.3121	0.1967
<i>XRN1</i>	3	rs12635931	G	0.9269	0.3957	0.49
<i>XRN1</i>	3	rs7349528	G	0.9569	0.5536	0.3518
<i>XRN1</i>	3	rs7642634	G	0.9495	0.5738	0.9038
<i>XRN1</i>	3	rs17621778	G	1.084	0.7441	0.8626
<i>XRN1</i>	3	rs2306700	A	0.9753	0.7819	0.892
<i>RABGEF1</i>	7	rs4717322	A	1.151	0.1076	0.2701
<i>RABGEF1</i>	7	GA006396	G	0.8145	0.2057	0.1767
<i>RABGEF1</i>	7	rs12536130	A	0.8397	0.2776	0.2333
<i>RABGEF1</i>	7	rs3778911	G	0.8398	0.2781	0.2319
<i>RABGEF1</i>	7	rs35315599	A	0.9079	0.2896	0.2689

## A $\beta$ toxicity modifier genes and the risk of AD

<i>RABGEF1</i>	7	rs4717319	A	0.9412	0.3331	0.4708
<i>RABGEF1</i>	7	rs2077180	G	0.9345	0.432	0.5984
<i>RABGEF1</i>	7	rs10234747	G	1.076	0.4422	0.3444
<i>RABGEF1</i>	7	rs1064795	A	1.071	0.4695	0.3711
<i>RABGEF1</i>	7	rs11028	G	0.9528	0.4772	0.505
<i>RABGEF1</i>	7	rs3823609	A	1.068	0.4867	0.3973
<i>RABGEF1</i>	7	rs10241395	A	1.039	0.6849	0.5526
<i>RABGEF1</i>	7	rs1060527	C	1.039	0.6849	0.5575
<i>RABGEF1</i>	7	rs1016265	A	1.02	0.7488	0.9475
<i>RABGEF1</i>	7	rs10479729	A	0.9895	0.902	0.9741
<i>SNX8</i>	7	rs2286206	A	1.554	0.01335	0.09287
<i>SNX8</i>	7	rs10249052	A	1.167	0.02036	0.04795
<i>SNX8</i>	7	rs4721524	G	1.296	0.1272	0.4121
<i>SNX8</i>	7	rs2398669	A	1.264	0.1727	0.518
<i>SNX8</i>	7	rs4719471	A	1.248	0.1921	0.6109
<i>SNX8</i>	7	rs4549678	A	0.9275	0.2375	0.3081
<i>SNX8</i>	7	rs12699820	A	1.065	0.335	0.4085
<i>SNX8</i>	7	rs4442022	G	0.9438	0.3884	0.7482
<i>SNX8</i>	7	rs12534131	A	1.045	0.4999	0.7426
<i>SNX8</i>	7	rs6963924	A	0.9569	0.5125	0.9266
<i>SNX8</i>	7	rs35932242	A	0.8151	0.5237	0.4023
<i>SNX8</i>	7	rs4866	A	0.8678	0.6062	0.9885
<i>SNX8</i>	7	rs2398668	A	1.033	0.6228	0.8276
<i>SNX8</i>	7	rs4721527	A	1.024	0.7137	0.9141
<i>SNX8</i>	7	rs7456643	G	0.9732	0.7282	0.8393
<i>SNX8</i>	7	rs10950641	A	0.9578	0.7681	0.7876
<i>SNX8</i>	7	rs6947645	A	0.9829	0.7897	0.7963
<i>SNX8</i>	7	rs1799832	A	0.9843	0.8407	0.8745
<i>PICALM</i>	11	rs10501602	G	0.7217	0.0006709	0.01037
<i>PICALM</i>	11	rs694011	A	0.839	0.008218	0.01608
<i>PICALM</i>	11	rs609903	A	0.8465	0.01206	0.01908
<i>PICALM</i>	11	rs10792820	C	1.146	0.05884	0.03251
<i>PICALM</i>	11	rs613222	C	1.114	0.08479	0.05787
<i>PICALM</i>	11	rs664629	G	0.9127	0.1468	0.2939
<i>PICALM</i>	11	rs10501604	A	1.123	0.1557	0.07547
<i>PICALM</i>	11	rs11234532	A	1.135	0.1862	0.2551
<i>PICALM</i>	11	rs642949	G	1.065	0.3254	0.1782
<i>PICALM</i>	11	rs622110	A	1.071	0.3262	0.4306
<i>PICALM</i>	11	rs1941375	G	1.063	0.376	0.4144
<i>PICALM</i>	11	rs10501603	G	1.068	0.3894	0.6031
<i>PICALM</i>	11	rs10898428	A	0.8963	0.41	0.2053
<i>PICALM</i>	11	rs10898431	A	1.057	0.4528	0.7721
<i>PICALM</i>	11	rs694353	A	1.046	0.477	0.9891
<i>PICALM</i>	11	rs540422	A	1.042	0.5127	0.9739
<i>PICALM</i>	11	rs592297	G	0.955	0.5601	0.3125

## A $\beta$ toxicity modifier genes and the risk of AD

<i>PICALM</i>	11	rs10128700	A	1.045	0.5698	0.8103
<i>PICALM</i>	11	rs17745273	G	1.044	0.5737	0.818
<i>PICALM</i>	11	rs10501605	G	1.043	0.5874	0.8181
<i>PICALM</i>	11	rs637304	A	0.9719	0.7183	0.4618
<i>PICALM</i>	11	rs2077815	G	0.9806	0.8017	0.5064
<i>PICALM</i>	11	rs17148741	A	0.9659	0.875	0.7259
<i>PICALM</i>	11	rs17148690	G	1.022	0.9223	0.994
<i>PICALM</i>	11	rs17148723	G	0.9943	0.9799	0.8922
<i>ADSSL1</i>	14	rs4983382	G	0.9188	0.2467	0.222
<i>ADSSL1</i>	14	rs4983540	A	1.064	0.4315	0.577
<i>ADSSL1</i>	14	rs6644	G	1.048	0.4525	0.6044
<i>ADSSL1</i>	14	rs11160818	A	0.9383	0.4749	0.2603
<i>ADSSL1</i>	14	rs3803307	G	1.042	0.5123	0.6585
<i>ADSSL1</i>	14	rs4983386	A	1.041	0.5173	0.6717
<i>ADSSL1</i>	14	rs4983384	A	0.9584	0.5291	0.4718
<i>ADSSL1</i>	14	rs12894569	A	1.062	0.531	0.6716
<i>ADSSL1</i>	14	rs9783669	A	1.07	0.5704	0.663
<i>ADSSL1</i>	14	rs35590716	A	1.054	0.5824	0.7838
<i>ADSSL1</i>	14	rs12432802	A	1.062	0.6344	0.7922
<i>ADSSL1</i>	14	rs34672588	A	1.021	0.7449	0.9351
<i>POMT2</i>	14	rs2363640	A	0.8732	0.07975	0.08041
<i>POMT2</i>	14	rs2270421	A	1.094	0.1864	0.1798
<i>POMT2</i>	14	rs2363641	G	1.09	0.1888	0.1688
<i>POMT2</i>	14	rs438931	A	0.8859	0.1996	0.2085
<i>POMT2</i>	14	rs1055592	A	1.103	0.2014	0.1983
<i>POMT2</i>	14	rs4141640	G	0.9105	0.2385	0.4576
<i>POMT2</i>	14	rs8015231	C	1.109	0.2543	0.2371
<i>POMT2</i>	14	rs10141995	A	1.173	0.2867	0.3166
<i>POMT2</i>	14	rs2193594	G	1.073	0.2937	0.2865
<i>POMT2</i>	14	rs6574363	A	1.163	0.3101	0.3579
<i>POMT2</i>	14	rs8177538	G	0.8942	0.3119	0.3936
<i>POMT2</i>	14	rs3209079	A	0.925	0.3315	0.5562
<i>POMT2</i>	14	rs3815625	A	0.9431	0.4595	0.7288
<i>POMT2</i>	14	rs2270419	G	0.9449	0.4741	0.739
<i>POMT2</i>	14	rs11547793	G	1.049	0.5185	0.4702
<i>POMT2</i>	14	rs4540995	G	0.9546	0.6392	0.2892
<i>POMT2</i>	14	rs2098380	G	1.03	0.6433	0.9483
<i>POMT2</i>	14	rs8177544	A	0.9311	0.6552	0.6006
<i>POMT2</i>	14	rs1861889	A	1.045	0.7104	0.9941
<i>POMT2</i>	14	rs3759733	A	1.024	0.7117	0.7028
<i>POMT2</i>	14	rs4899651	A	1.02	0.7862	0.8779
<i>POMT2</i>	14	rs2216089	A	0.9858	0.8193	0.7985
<i>POMT2</i>	14	rs11624564	G	1.014	0.827	0.4847
<i>POMT2</i>	14	rs7158951	G	0.9864	0.8275	0.7683
<i>POMT2</i>	14	rs3783986	A	1.01	0.8807	0.8536

## A $\beta$ toxicity modifier genes and the risk of AD

<i>POMT2</i>	14	rs17105685	A	1.01	0.8997	0.9872
<i>POMT2</i>	14	rs7159558	G	0.9938	0.9218	0.6689
<i>POMT2</i>	14	rs17105672	A	0.9943	0.9308	0.8031
<i>POMT2</i>	14	rs2287388	A	1	0.9976	0.8958
<i>PPP2R5C</i>	14	rs1746595	G	1.235	0.004142	0.009017
<i>PPP2R5C</i>	14	rs1678031	A	1.27	0.04928	0.06185
<i>PPP2R5C</i>	14	rs1741140	A	1.158	0.1368	0.2106
<i>PPP2R5C</i>	14	rs1746587	G	1.152	0.1383	0.07324
<i>PPP2R5C</i>	14	rs1741143	A	1.167	0.1566	0.2385
<i>PPP2R5C</i>	14	rs1058327	G	1.154	0.165	0.1931
<i>PPP2R5C</i>	14	rs12436919	A	0.8663	0.1997	0.4091
<i>PPP2R5C</i>	14	rs1678018	G	1.17	0.2832	0.4172
<i>PPP2R5C</i>	14	rs1618921	A	1.105	0.3148	0.3171
<i>PPP2R5C</i>	14	rs1677999	G	0.9331	0.3332	0.2778
<i>PPP2R5C</i>	14	rs3783370	A	0.9062	0.3704	0.2212
<i>PPP2R5C</i>	14	rs3742424	C	0.9025	0.3756	0.1744
<i>PPP2R5C</i>	14	rs736449	A	0.9284	0.483	0.3647
<i>PPP2R5C</i>	14	rs2749902	G	1.063	0.5264	0.5519
<i>PPP2R5C</i>	14	rs2720219	G	1.051	0.5352	0.8475
<i>PPP2R5C</i>	14	rs1612684	A	1.048	0.545	0.7333
<i>PPP2R5C</i>	14	rs1677991	G	1.047	0.5469	0.9285
<i>PPP2R5C</i>	14	rs10132483	G	1.053	0.6029	0.3632
<i>PPP2R5C</i>	14	rs2251246	A	1.049	0.6091	0.6046
<i>PPP2R5C</i>	14	rs2720208	G	1.03	0.6893	0.9306
<i>PPP2R5C</i>	14	rs1904298	A	1.051	0.693	0.9957
<i>PPP2R5C</i>	14	rs8003511	A	1.039	0.7011	0.4559
<i>PPP2R5C</i>	14	rs7145618	G	0.954	0.7121	0.8657
<i>PPP2R5C</i>	14	rs2720202	G	1.033	0.7245	0.9784
<i>PPP2R5C</i>	14	rs8015021	A	1.032	0.77	0.3977
<i>PPP2R5C</i>	14	rs1678019	G	0.98	0.7732	0.9625
<i>PPP2R5C</i>	14	rs1677998	A	0.9656	0.7879	0.9977
<i>PPP2R5C</i>	14	rs2749907	A	0.9827	0.8029	0.7234
<i>PPP2R5C</i>	14	rs7142002	G	1.031	0.8187	0.6298
<i>PPP2R5C</i>	14	rs961495	G	0.9833	0.8344	0.6537
<i>PPP2R5C</i>	14	rs6575883	G	1.002	0.9856	0.6059
<i>MAP2K4</i>	17	rs28921114	I	1.498	0.1387	0.1342
<i>MAP2K4</i>	17	rs10445266	G	0.9293	0.244	0.6917
<i>MAP2K4</i>	17	rs10432016	A	0.933	0.2718	0.6777
<i>MAP2K4</i>	17	rs12942507	A	1.073	0.2895	0.5588
<i>MAP2K4</i>	17	rs976244	G	0.931	0.3335	0.7225
<i>MAP2K4</i>	17	rs9788973	A	0.9412	0.3364	0.8473
<i>MAP2K4</i>	17	rs7216812	A	1.058	0.376	0.803
<i>MAP2K4</i>	17	rs1034870	C	0.9372	0.3807	0.8049
<i>MAP2K4</i>	17	rs10445268	A	0.9442	0.4024	0.6801
<i>MAP2K4</i>	17	rs7207011	G	0.8628	0.4173	0.5393

## A $\beta$ toxicity modifier genes and the risk of AD

MAP2K4	17	rs1017743	A	1.043	0.5403	0.5554
MAP2K4	17	rs17541807	G	0.9651	0.5866	0.8125
MAP2K4	17	rs12051769	G	0.9716	0.6889	0.9164
MAP2K4	17	rs757594	G	0.9716	0.6891	0.9465
MAP2K4	17	rs4791489	A	1.025	0.6991	0.9116
MAP2K4	17	rs12603036	A	1.04	0.7021	0.7012
MAP2K4	17	rs8065164	G	1.023	0.7304	0.6713
MAP2K4	17	rs2322123	G	0.9809	0.788	0.8942
SYNJ1	21	rs2833930	A	0.9047	0.1407	0.05831
SYNJ1	21	rs2254562	G	0.9146	0.1897	0.08072
SYNJ1	21	rs845023	G	1.18	0.2102	0.1171
SYNJ1	21	rs10470165	G	1.165	0.2447	0.1362
SYNJ1	21	rs860077	C	1.074	0.2501	0.3
SYNJ1	21	rs2833935	G	1.072	0.2535	0.2133
SYNJ1	21	rs2833931	A	0.9347	0.2683	0.2057
SYNJ1	21	SNP21-32975832	T	1.153	0.2784	0.1629
SYNJ1	21	rs11702774	A	0.9304	0.3306	0.1335
SYNJ1	21	rs2833934	A	0.8542	0.3497	0.358
SYNJ1	21	rs648648	A	1.089	0.3785	0.1837
SYNJ1	21	rs607020	A	1.042	0.4989	0.4749
SYNJ1	21	rs845022	A	1.041	0.5113	0.4842
SYNJ1	21	rs17694546	A	1.009	0.9447	0.4732
SYNJ1	21	rs844996	G	1.007	0.9455	0.8656
SH3KBP1	X	rs12013533	G	0.7977	0.006109	0.01496
SH3KBP1	X	rs1017874	A	0.7876	0.01772	0.04958
SH3KBP1	X	rs6629352	G	0.8188	0.01957	0.05905
SH3KBP1	X	rs6527933	C	0.826	0.02229	0.0292
SH3KBP1	X	rs10127144	G	0.8282	0.0278	0.05364
SH3KBP1	X	rs16981251	G	0.8277	0.02933	0.0665
SH3KBP1	X	rs5955826	A	0.8321	0.0342	0.07057
SH3KBP1	X	rs7062445	G	0.8372	0.04156	0.05499
SH3KBP1	X	rs4630061	G	0.8252	0.05452	0.0455
SH3KBP1	X	rs5955812	G	0.859	0.0621	0.06608
SH3KBP1	X	rs6527940	A	0.8347	0.06729	0.05181
SH3KBP1	X	rs7888444	A	0.8254	0.07836	0.09562
SH3KBP1	X	rs16981279	C	0.8389	0.1017	0.1275
SH3KBP1	X	rs11094775	A	0.8511	0.1049	0.09655
SH3KBP1	X	rs900686	A	0.8505	0.1075	0.0873
SH3KBP1	X	rs7889157	C	0.8614	0.1555	0.1782
SH3KBP1	X	rs16981266	G	0.8743	0.1694	0.1562
SH3KBP1	X	rs4825317	G	0.883	0.2375	0.3003
SH3KBP1	X	rs11796420	A	1.198	0.2627	0.3501
SH3KBP1	X	rs5955819	A	0.9043	0.3657	0.4975
SH3KBP1	X	rs11795873	G	1.061	0.3879	0.6763
SH3KBP1	X	rs5909133	G	0.9905	0.9404	0.9418

<sup>1</sup>Chromosome location; <sup>2</sup> Effect allele; <sup>3</sup>Odds ratio; <sup>4</sup>Unadjusted P-value; <sup>5</sup>APOE adjusted P-value

## A $\beta$ toxicity modifier genes and the risk of AD

**Supplementary Table 2.** Significant windows in five genes in haplotype analysis

Gene	Window <sup>1</sup>	Haplotype	Control Frequency	Case Frequency	Total Frequency	Global P <sup>2</sup>	
SNX8 (15) <sup>3</sup>	rs4549678	AAAA	0.001967849	0.005011279	0.004045297	0.042122	
	rs12699820	AAAG	NA	0.001320437	0.000589227		
	rs10950641	AAGA	0.025940599	0.027085454	0.02631246		
	rs10249052	AAGG	0.031026958	0.02187551	0.025965494		
		ACAA	NA	2.84E-10	7.49E-12		
		ACAG	NA	1.27E-10	2.82E-10		
		ACGA	0.003308397	0.005871904	0.004719863		
		ACGG	0.373038034	0.348636043	0.359024728		
		GAAA	0.044447955	0.03936929	0.041324651		
		GAAG	0.000643274	3.43E-10	0.000316542		
		GAGA	0.211471931	0.251248349	0.234466017		
		GAGG	0.011561002	0.008191831	0.009505745		
		GCAG	NA	NA	2.52E-13		
		GCGA	0.008792288	0.009136419	0.009051677		
		GCGG	0.287801714	0.282253483	0.284678298		
	rs10950641	AAAG	0.004873169	0.003484862	0.004081811	0.047033	
	rs10249052	AAGA	0.041483774	0.04112434	0.041295962		
	rs6963924	AGAG	0.000693093	0.000506895	0.00047377		
	rs4442022	AGGA	2.64E-08	0.000586101	0.000422255		
		GAAA	0.000526522	NA	1.39E-09		
		GAAG	0.00837652	0.012893169	0.010926271		
		GAGA	0.238963073	0.278087463	0.261627069		
		GAGG	0.001705961	0.002132861	0.00198885		
		GGAA	9.45E-11	0.000781038	0.000672245		
		GGAG	0.289288525	0.277454098	0.282645367		
		GGGA	0.410047352	0.380810492	0.392954264		
		GGGG	0.004041985	0.00213868	0.002912134		
	rs4721524	AAGA	NA	0.001551279	0.000895151		0.049016
	rs2286206	AAGG	NA	1.66E-10	1.17E-10		
	rs4721527	AGAA	3.88E-10	0.000493691	0.000287401		
	rs6947645	AGAG	0.362181986	0.368034236	0.365563037		

## A $\beta$ toxicity modifier genes and the risk of AD

		AGGA	0.391962421	0.377118468	0.383432833		
		AGGG	0.215062273	0.211748878	0.213138608		
		GAGG	0.030793319	0.040661951	0.036444584		
		GGAG	NA	3.44E-09	2.10E-09		
		GGGG	NA	0.000391493	0.000238384		
<i>PICALM</i> (22)	rs2077815	AAAA	0.165970772	0.178931061	0.173410405	0.036627	
	rs10501602	AAAG	0.286319737	0.293931393	0.290680662		
	rs10501603	AAGG	0.212943632	0.226181115	0.220542347		
	rs10501604	AGAG	0.134655532	0.104984177	0.117633241		
		AGGG	NA	1.40E-07	1.16E-07		
		GAAG	0.200110326	0.194837144	0.197091797		
		GGAG	NA	0.00113497	0.000641432		
		GGGG	NA	8.72E-11	6.19E-12		
		rs10501602	AAAG	0.165970772	0.178931061	0.173410405	0.038324
		rs10501603	AAGA	0.194154488	0.188048902	0.190651631	
		rs10501604	AAGG	0.292275575	0.300719618	0.297120797	
		rs540422	AGGG	0.212943632	0.226181132	0.220542378	
			GAGA	NA	0.000564576	0.000322135	
			GAGG	0.134655532	0.105554588	0.117952568	
		GGGA	NA	2.91E-11	3.77E-13		
		GGGG	NA	1.23E-07	8.52E-08		
	rs622110	AAAA	0.262526096	0.271882262	0.267896843	0.039749	
	rs2077815	GAAA	0.189711167	0.20083557	0.196092084		
	rs10501602	GAAG	0.212943632	0.226181119	0.220542343		
	rs10501603	GAGA	0.134655532	0.105128799	0.117713741		
		GAGG	NA	1.36E-07	1.21E-07		
		GGAA	0.200163572	0.194981762	0.197193942		
		GGGA	NA	0.000990353	0.000560927		
<i>PPP2R5C</i> (28)	rs1677999	AAAG	0.063391664	0.064507676	0.064008472	0.005107	
	rs1741140	AAGA	NA	1.40E-10	1.39E-10		
	rs2749907	AGAA	0.034341792	0.032584991	0.033403633		
	rs1677991	AGAG	0.014844765	0.006825857	0.010207884		

Aβ toxicity modifier genes and the risk of AD

		AGGA	0.620119275	0.629882955	0.625750132	
		AGGG	0.001331486	0.001171362	0.001200625	
		GAAG	0.036295183	0.044682219	0.041135104	
		GAGA	NA	0.000415063	0.000236593	
		GGAA	0.040807906	0.021516368	0.029611797	
		GGAG	0.056312378	0.071556012	0.065132879	
		GGGA	0.109532697	0.111211203	0.110539311	
		GGGG	0.023022854	0.015646296	0.01877357	
<i>ADSSL1</i>	rs11160818	AAGG	0.002949317	0.001600814	0.002238167	0.003724
(9)	rs4983382	AGAA	9.32E-08	0.000738023	0.00064964	
	rs35590716	AGGA	0.110873113	0.106567255	0.1082767	
	rs34672588	AGGG	0.028310888	0.026531381	0.02722083	
		GAAA	0.113778612	0.117949668	0.11606806	
		GAGA	0.129372836	0.123813999	0.126047563	
		GAGG	0.506171054	0.523753859	0.516592627	
		GGAA	NA	0.000147006	8.41E-07	
		GGGA	0.089057792	0.095284265	0.092977537	
		GGGG	0.019486293	0.003497369	0.009928036	
<i>SH3KBP1</i> -males	rs16981251	AAAA	0.001519772	0.006277048	0.004299646	0.007823
(19)	rs4630061	AAAG	0.496120256	0.459794796	0.475190379	
	rs11795873	AAGG	0.28596621	0.375912941	0.337784912	
	rs11094775	AGAG	NA	0.004249524	0.00244524	
		GAAA	0.004162117	0.0041841	0.004134558	
		GAGA	1.18E-08	NA	5.50E-11	
		GAGG	0.058822544	0.046090529	0.051482072	
		GGAA	0.1505681	0.096233412	0.11927664	
		GGAG	0.002840991	0.00478491	0.003995133	
		GGGG	NA	0.002472739	0.001391422	
	rs4630061	AAAA	0.002841063	0.004184631	0.003614743	0.009882
	rs11795873	AAAC	0.002840839	0.006276151	0.0048194	
	rs11094775	AAGC	0.495993753	0.45966633	0.475055004	
	rs900686	AGAC	6.97E-08	NA	8.46E-11	
		AGGC	0.344915184	0.422132302	0.38940242	



## Aβ toxicity modifier genes and the risk of AD

	GAAA	0.150568028	0.096233779	0.1192767	
	GAGA	NA	0.0041841	0.002409762	
	GAGC	0.002841063	0.004857865	0.004039601	
rs7062445	AAAA	0.498896655	0.465796895	0.479827672	0.010463
rs16981251	AAAG	0.282353345	0.372054332	0.334017814	
rs4630061	AAGA	NA	0.004198983	0.00241502	
rs11795873	AGAA	NA	0.00209205	0.001205028	
	AGAG	NA	0.00209205	0.001209165	
	GAAG	0.002840909	0.0041841	0.003614667	
	GGAA	0.002917515	0.00209205	0.002449046	
	GGAG	0.059582485	0.043947937	0.050568174	
	GGGA	0.153409091	0.101367898	0.123463165	
	GGGG	NA	0.002173705	0.001230249	
rs7888444	ACGC	0.130681818	0.082635983	0.103012048	0.01372
rs16981279	CAAA	0.865056818	0.89958159	0.884939759	
rs4825317	CAGC	NA	0.012552301	0.007228916	
rs7889157	CCGC	0.004261364	0.005230126	0.004819277	
rs11795873	AAAG	0.153354978	0.10041841	0.122855881	0.013747
rs11094775	AACA	5.18E-08	0.0041841	0.003012123	
rs900686	AACG	0.001474567	0.00209205	0.001842839	
rs16981266	AGAG	NA	0.0041841	0.002409713	
	AGCA	0.497419054	0.459287111	0.474874265	
	AGCG	0.002840909	0.005230125	0.004216867	
	GACA	0.001420403	NA	1.37E-10	
	GGCA	0.343490037	0.424604102	0.39078831	
	GGCG	NA	1.74E-10	2.02E-11	
rs16981279	AAAA	0.019887477	0.014646082	0.016868915	0.041451
rs4825317	AAAG	0.845169341	0.884935508	0.868070844	
rs7889157	AGCA	NA	0.0041841	0.002409639	
rs1017874	AGCG	NA	0.008368201	0.004819277	
	CAAA	1.57E-10	NA	4.67E-12	
	CGCA	0.130589038	0.083680278	0.103565348	
	CGCG	0.004354143	0.004185831	0.004265977	

<sup>1</sup>Four SNPs represented in the haplotype window; <sup>2</sup>P value for association of all haplotypes at corresponding four SNPs tested; <sup>3</sup>Number of windows tested in gene.